Sapporo Clinical Laboratory Inc. said its normalized net income for the fiscal third quarter ended Dec. 31, 2014, came to ¥36.46 per share, a decrease of 19.4% from ¥45.24 per share in the prior-year period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥136.9 million, a decline of 24.0% from ¥180.0 million in the year-earlier period.
The normalized profit margin declined to 3.1% from 4.2% in the year-earlier period.
Total revenue rose year over year to ¥4.35 billion from ¥4.31 billion, and total operating expenses rose from the prior-year period to ¥4.14 billion from ¥4.02 billion.
Reported net income declined 19.9% on an annual basis to ¥133.0 million, or ¥35.43 per share, from ¥166.0 million, or ¥41.72 per share.
As of Feb. 13, US$1 was equivalent to ¥118.68.
